Melatonin influences the biological characteristics of keloid fibroblasts through the Erk and Smad signalling pathways

Abstract

Background: Keloids are abnormal fibrous hyperplasias that are difficult to treat. Melatonin can be used to inhibit the development of certain fibrotic diseases but has never been used to treat keloids. We aimed to discover the effects and mechanisms of melatonin in keloid fibroblasts (KFs). Methods: Flow cytometry, CCK-8 assays, western blotting, wound-healing assays, transwell assays, collagen gel contraction assays and immunofluorescence assays were applied to demonstrate the effects and mechanisms of melatonin in fibroblasts derived from normal skin, hypertrophic scars and keloids. The therapeutic potential of the combination of melatonin and 5-fluorouracil (5-FU) was investigated in KFs. Results: Melatonin significantly promoted cell apoptosis and inhibited cell proliferation, migration and invasion, contractile capability and collagen production in KFs. Further mechanistic studies demonstrated that melatonin could inhibit the cAMP/PKA/Erk and Smad pathways through the membrane receptor MT2 to alter the biological characteristics of KFs. Moreover, the combination of melatonin and 5-FU remarkably promoted cell apoptosis and inhibited cell migration and invasion, contractile capability and collagen production in KFs. Furthermore, 5-FU suppressed the phosphorylation of Akt, mTOR, Smad3 and Erk, and melatonin in combination with 5-FU markedly suppressed the activation of the Akt, Erk and Smad pathways. Conclusions: Collectively, melatonin may inhibit the Erk and Smad pathways through the membrane receptor MT2 to alter the cell functions of KFs, while combination with 5-FU could exert even more inhibitory effects in KFs through simultaneous suppression of multiple signalling pathways.

Keywords

Keloid / Fibroblast / Melatonin / 5-fluorouracil / Erk / Smad / Signalling pathways / Hyperplasias / Phosphorylation

References

[1] Rockwell WB, Cohen IK, Ehrlich HP. Keloids and hypertrophic scars: a comprehensive review. Plast Reconstr Surg. 1989; 84: 827-37.

[2] Robles DT, Berg D. Abnormal wound healing: keloids. Clin Dermatol. 2007; 25: 26-32.

[3] Niessen FB, Spauwen PH, Schalkwijk J, Kon M. On the nature of hypertrophic scars and keloids: a review. Plast Reconstr Surg. 1999; 104: 1435-58.

[4] Oluwasanmi JO. Keloids in the African. Clin Plast Surg. 1974; 1: 179-95.

[5] Jung JY, Roh MR, Kwon YS, Chung KY. Surgery and perioperative intralesional corticosteroid injection for treating earlobe keloids: a korean experience. Ann Dermatol. 2009; 21: 221-5.

[6] Lee YI, Kim J, Yang CE, Hong JW, Lee WJ, Lee JH. Combined therapeutic strategies for keloid treatment. Dermatol Surg. 2019; 45: 802-10.

[7] Singer AJ, Clark RA. Cutaneous wound healing. N Engl J Med. 1999; 341: 738-46.

[8] Shah M, Foreman DM, Ferguson MW. Neutralising antibody to TGF-beta 1,2 reduces cutaneous scarring in adult rodents. J Cell Sci. 1994; 107: 1137-57.

[9] Naim R, Naumann A, Barnes J, Sauter A, Hormann K, Merkel D, et al. Transforming growth factor-beta1-antisense modulates the expression of hepatocyte growth factor/scatter factor in keloid fibroblast cell culture. Aesthet Plast Surg. 2008; 32: 346-52.

[10] Shah M, Foreman DM, Ferguson MW. Neutralisation of TGF-beta 1 and TGF-beta 2 or exogenous addition of TGF-beta 3 to cutaneous rat wounds reduces scarring. J Cell Sci. 1995; 108: 985-1002.

[11] Wulandari E, Jusman SW, Moenadjat Y, Jusuf AA, Sadikin M. Expressions of collagen I and III in hypoxic keloid tissue. Kobe J Med Sci. 2016; 62: E58-69.

[12] da Silva IR, Tiveron L, da Silva MV, Peixoto AB, Carneiro CAX, Dos Reis MA, et al. In situ cytokine expression and morphometric evaluation of Total collagen and collagens type I and type III in keloid scars. Mediat Inflamm. 2017; 2017: 6573802.

[13] Wang YZ, Su C, Fu SQ, Liu LQ. Research advances on the characteristics of fibroblast in keloid. Zhonghua Shao Shang Za Zhi. 2022; 38: 590-4.

[14] Syed F, Sanganee HJ, Singh S, Bahl A, Bayat A. Potent dual inhibitors of TORC1 and TORC2 complexes (KU-0063794 and KU-0068650) demonstrate in vitro and ex vivo anti-keloid scar activity. J Invest Dermatol. 2013; 133: 1340-50.

[15] Wong VW, You F, Januszyk M, Gurtner GC, Kuang AA. Transcriptional profiling of rapamycin-treated fibroblasts from hypertrophic and keloid scars. Ann Plast Surg. 2014; 72: 711-9.

[16] Syed F, Sherris D, Paus R, Varmeh S, Singh S, Pandolfi PP, et al. Keloid disease can be inhibited by antagonizing excessive mTOR signaling with a novel dual TORC1/2 inhibitor. Am J Pathol. 2012; 181: 1642-58.

[17] Wang W, Qu M, Xu L, Wu X, Gao Z, Gu T, et al. Sorafenib exerts an anti-keloid activity by antagonizing TGF-beta/Smad and MAPK/ERK signaling pathways. J Mol Med (Berl). 2016; 94: 1181-94.

[18] Hardeland R, Balzer I, Poeggeler B, Fuhrberg B, Uria H, Behrmann G, et al. On the primary functions of melatonin in evolution: mediation of photoperiodic signals in a unicell, photooxidation, and scavenging of free radicals. J Pineal Res. 1995; 18: 104-11.

[19] Kang JW, Hong JM, Lee SM. Melatonin enhances mitophagy and mitochondrial biogenesis in rats with carbon tetrachloride-induced liver fibrosis. J Pineal Res. 2016; 60: 383-93.

[20] Li J, Li N, Yan S, Lu Y, Miao X, Gu Z, et al. Melatonin attenuates renal fibrosis in diabetic mice by activating the AMP-K/PGC1alpha signaling pathway and rescuing mitochondrial function. Mol Med Rep. 2019; 19: 1318-30.

[21] Matsuhashi N, Saio M, Matsuo A, Sugiyama Y, Saji S. Apoptosis induced by 5-fluorouracil, cisplatin and paclitaxel are associated with p53 gene status in gastric cancer cell lines. Int J Oncol. 2005; 26: 1563-7.

[22] Wendling J, Marchand A, Mauviel A, Verrecchia F. 5-fluorouracil blocks transforming growth factor-beta-induced alpha 2 type I collagen gene (COL1A2) expression in human fibroblasts via c-Jun NH2-terminal kinase/activator protein-1 activation. Mol Pharmacol. 2003; 64: 707-13.

[23] Fitzpatrick RE. Treatment of inflamed hypertrophic scars using intralesional 5-FU. Dermatol Surg. 1999; 25: 224-32.

[24] Grabowski G, Pacana MJ, Chen E. Keloid and hypertrophic scar formation, prevention, and management: standard review of abnormal scarring in orthopaedic surgery. J Am Acad Orthop Surg. 2020; 28: e408-14.

[25] Limandjaja GC, Niessen FB, Scheper RJ, Gibbs S. The keloid disorder: heterogeneity, histopathology, mechanisms and models. Front Cell Dev Biol. 2020; 8: 360.

[26] Berman B, Maderal A, Raphael B. Keloids and hypertrophic scars: pathophysiology, classification, and treatment. Dermatol Surg. 2017; 43: S3-18.

[27] Wu JJ, Sun ZL, Liu SY, Chen ZH, Yuan ZD, Zou ML, et al. The ASIC3-M-CSF-M2 macrophage-positive feedback loop modulates fibroblast-to-myofibroblast differentiation in skin fibrosis pathogenesis. Cell Death Dis. 2022; 13: 527.

[28] Shi F, Cao X, Hu Z, Ma D, Guo D, Zhang J, et al. Pleiotropic FTY720 is a specific and potent therapy for hypertrophic scars. J Invest Dermatol. 2017; 137: 1552-61.

[29] Pal R, Mamidi MK, Das AK, Bhonde R. Diverse effects of dimethyl sulfoxide (DMSO) on the differentiation potential of human embryonic stem cells. Arch Toxicol. 2012; 86: 651-61.

[30] Unahabhokha T, Sucontphunt A, Nimmannit U, Chanvorachote P, Yongsanguanchai N, Pongrakhananon V. Molecular signalings in keloid disease and current therapeutic approaches from natural based compounds. Pharm Biol. 2015; 53: 457-63.

[31] Zhang Z, Nie F, Kang C, Chen B, Qin Z, Ma J, et al. Increased periostin expression affects the proliferation, collagen synthesis, migration and invasion of keloid fibroblasts under hypoxic conditions. Int J Mol Med. 2014; 34: 253-61.

[32] Vanecek J, Vollrath L. Melatonin inhibits cyclic AMP and cyclic GMP accumulation in the rat pituitary. Brain Res. 1989; 505: 157-9.

[33] Yulia A, Singh N, Lei K, Sooranna SR, Johnson MR.Cyclic AMP effectors regulate Myometrial oxytocin receptor expression. Endocrinology. 2016; 157: 4411-22.

[34] Almahariq M, Mei FC, Cheng X. Cyclic AMP sensor EPAC proteins and energy homeostasis. Trends Endocrinol Metab. 2014; 25: 60-71.

[35] Formosa R, Vassallo J. cAMP signalling in the normal and tumorigenic pituitary gland. Mol Cell Endocrinol. 2014; 392: 37-50.

[36] Taylor SS, Zhang P, Steichen JM, Keshwani MM, Kornev AP. PKA: lessons learned after twenty years. Biochim Biophys Acta. 2013; 1834: 1271-8.

[37] Shih B, Garside E, McGrouther DA, Bayat A. Molecular dissection of abnormal wound healing processes resulting in keloid disease. Wound Repair Regen. 2010; 18: 139-53.

[38] Gauglitz GG, Korting HC, Pavicic T, Ruzicka T, Jeschke MG.Hypertrophic scarring and keloids: pathomechanisms and current and emerging treatment strategies. Mol Med. 2011; 17: 113-25.

[39] Chin GS, Liu W, Peled Z, Lee TY, Steinbrech DS, Hsu M, et al. Differential expression of transforming growth factor-beta receptors I and II and activation of Smad 3 in keloid fibroblasts. Plast Reconstr Surg. 2001; 108: 423-9.

[40] Bettinger DA, Yager DR, Diegelmann RF, Cohen IK. The effect of TGF-beta on keloid fibroblast proliferation and collagen synthesis. Plast Reconstr Surg. 1996; 98: 827-33.

[41] Meng XM, Nikolic-Paterson DJ, Lan HY. TGF-beta: the master regulator of fibrosis. Nat Rev Nephrol. 2016; 12: 325-38.

[42] He S, Liu X, Yang Y, Huang W, Xu S, Yang S, et al. Mechanisms of transforming growth factor beta(1)/Smad signalling mediated by mitogen-activated protein kinase pathways in keloid fibroblasts. Br J Dermatol. 2010; 162: 538-46.

[43] Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature. 2003; 425: 577-84.

[44] Lee CM, Park JW, Cho WK, Zhou Y, Han B, Yoon PO, et al. Modifiers of TGF-beta1 effector function as novel therapeutic targets of pulmonary fibrosis. Korean J Intern Med. 2014; 29: 281-90.

[45] Mulsow JJ, Watson RW, Fitzpatrick JM, O’Connell PR. Transforming growth factor-beta promotes pro-fibrotic behavior by serosal fibroblasts via PKC and ERK1/2 mitogen activated protein kinase cell signaling. Ann Surg. 2005; 242: 880-7 discussion 7-9.

[46] Ebisawa T, Karne S, Lerner MR, Reppert SM. Expression cloning of a high-affinity melatonin receptor from Xenopus dermal melanophores. Proc Natl Acad Sci U S A. 1994; 91: 6133-7.

[47] Hu W, Ma Z, Jiang S, Fan C, Deng C, Yan X, et al. Melatonin: the dawning of a treatment for fibrosis? J Pineal Res. 2016; 60: 121-31.

[48] Kim JY, Park JH, Jeon EJ, Leem J, Park KK. Melatonin prevents transforming growth factor-beta1-stimulated Transdifferentiation of renal interstitial fibroblasts to Myofibroblasts by suppressing reactive oxygen species-dependent mechanisms. Antioxidants (Basel). 2020; 9: 39.

[49] Supp DM. Animal models for studies of keloid scarring. Adv Wound Care (New Rochelle). 2019; 8: 77-89.

[50] Attia YM, El-Kersh DM, Wagdy HA, Elmazar MM. Verbascoside: identification, quantification, and potential sensitization of colorectal cancer cells to 5-FU by targeting PI3K/AKT pathway. Sci Rep. 2018; 8: 16939.

[51] Gao Y, Xiao X, Zhang C, Yu W, Guo W, Zhang Z, et al. Melatonin synergizes the chemotherapeutic effect of 5-fluorouracil in colon cancer by suppressing PI3K/AKT and NF-kappaB/iNOS signaling pathways. J Pineal Res. 2017; 62: e12380.

[52] Liu X, Dong C, Ma S, Wang Y, Lin T, Li Y, et al. Nanocomplexes loaded with miR-128-3p for enhancing chemotherapy effect of colorectal cancer through dual-targeting silence the activity of PI3K/AKT and MEK/ERK pathway. Drug Deliv. 2020; 27: 323-33.

[53] Liu X, Dong C, Ma S, Wang Y, Lin T, Li Y, et al. Nanocomplexes loaded with miR-128-3p for enhancing chemotherapy effect of colorectal cancer through dual-targeting silence the activity of PI3K/AKT and MEK/ERK pathway. Drug Deliv. 2020; 27: 323-33.